Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRE | P78334 | 2/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27681605 | 0.84 | GABRP (0.31) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6766740 | 0.82 | GABRP (0.30) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4114676 | 0.82 | — | — | |
| SCHEMBL717707 | 0.82 | — | — | |
| SCHEMBL16654271 | 0.80 | — | — | |
| SCHEMBL2354839 | 0.80 | — | — | |
| SCHEMBL14520488 | 0.80 | — | — | |
| SCHEMBL20197695 | 0.80 | — | — | |
| SCHEMBL2354840 | 0.80 | — | — | |
| SCHEMBL14307543 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204436-A1 | POLYMER PRODUCT, METHOD FOR PRODUCING THE POLYMER AND USE OF THE POLYMER | Kemira OYJ (FI) | 2017-08-16 | — | — | EP | claimed |
| WO-2016055691-A1 | POLYMER PRODUCT, METHOD FOR PRODUCING THE POLYMER AND USE OF THE POLYMER | KEMIRA OYJ (FI) | 2016-04-14 | — | — | WO | claimed |
| EP-2376092-A2 | POLYVINYLPYRROLIDONE AS A THERAPEUTICALLY ACTIVE COMPOUND FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING BACTERIAL, VIRAL AND FUNGAL PATHOGENS | Mergemeier, Steffen (DE) | 2011-10-19 | — | — | EP | claimed |
| WO-2010054858-A2 | POLYVINYLPYRROLIDONE AS A THERAPEUTICALLY ACTIVE COMPOUND FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING BACTERIAL, VIRAL AND FUNGAL PATHOGENS | MERGEMEIER STEFFEN (DE) | 2010-05-20 | — | — | WO | claimed |
| EP-2186521-A1 | Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound | Steffen, Mergemeier (DE) | 2010-05-19 | — | — | EP | claimed |
| US-7125547-B2 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION (US) | 2006-10-24 | — | — | US | claimed |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION | 2004-08-05 | — | — | US | claimed |
| US-6726905-B1 | LOWERING SERUM PHOSPHATE | GENZYME CORPORATION | 2004-04-27 | — | — | US | claimed |
| US-6610283-B1 | Method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a | GENZYME CORPORATION | 2003-08-26 | — | — | US | claimed |
| EP-1043981-B1 | FAT-BINDING POLYMERS COMBINED WITH LIPASE INHIBITORS FOR THE TREATMENT OF OBESITY | GELTEX PHARMA INC (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | GELTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | claimed |
| US-6290947-B1 | IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| EP-0716606-B1 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMA INC (US) | 2001-08-29 | — | — | EP | claimed |
| US-6264937-B1 | MIXTURE WITH LIPASE INHIBITOR | GELTEX PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | claimed |
| US-6203785-B1 | ADMINISTERING CROSSLINKED CATIONIC POLYMER ANTICHOLESTEROL AGENTS | GELTEX PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | claimed |
| EP-1043981-A2 | FAT-BINDING POLYMERS COMBINED WITH LIPASE INHIBITORS | Geltex Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5925379-A | REMOVING BILE SALTS FROM PATIENT BY ADMINISTERING INTERPENETRATING POLYMER NETWORK COMPRISING CATIONIC POLYMER | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | claimed |
| WO-1999034787-A2 | FAT-BINDING POLYMERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-15 | — | — | WO | claimed |
| WO-1999022743-A1 | POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | claimed |
| WO-2023048115-A1 | BLOOD CELL SEPARATION AGENT, AND BLOOD CELL SEPARATION METHOD USING SAME | 日東紡績株式会社 | 2023-03-30 | — | — | WO | disclosed |
| US-11186685-B2 | Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles | FUJIFILM CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| EP-3564292-B1 | EMULSION OF NITROGEN ATOM-CONTAINING POLYMER OR SALT THEREOF, PRODUCTION METHOD THEREFOR, AND PRODUCTION METHOD FOR PARTICLES | FUJIFILM CORP (JP) | 2021-06-16 | — | — | EP | disclosed |
| EP-3564292-A1 | EMULSION OF NITROGEN ATOM-CONTAINING POLYMER OR SALT THEREOF, PRODUCTION METHOD THEREFOR, AND PRODUCTION METHOD FOR PARTICLES | Fujifilm Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20190315932-A1 | EMULSION OF NITROGEN ATOM-CONTAINING POLYMER OR SALT THEREOF, PRODUCTION METHOD THEREFOR, AND PRODUCTION METHOD FOR PARTICLES | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| CN-107614019-A | For combining the polymeric medicine conjugate of anti-cancer therapies | 加利福尼亚大学董事会 | 2018-01-19 | — | — | CN | disclosed |
| CN-103387833-B | Form method and the liquid crystal display cells of light orientation liquid crystal orienting film | 捷恩智株式会社 | 2016-08-24 | — | — | CN | disclosed |
| EP-2376092-A2 | POLYVINYLPYRROLIDONE AS A THERAPEUTICALLY ACTIVE COMPOUND FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING BACTERIAL, VIRAL AND FUNGAL PATHOGENS | Mergemeier, Steffen (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20100266526-A1 | Combination therapy for treating hypercholesterolemia | GENZYME CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100172861-A1 | Anionic Polymers as Toxin Binders and Antibacterial Agents | GENZYME CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010054858-A2 | POLYVINYLPYRROLIDONE AS A THERAPEUTICALLY ACTIVE COMPOUND FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING BACTERIAL, VIRAL AND FUNGAL PATHOGENS | MERGEMEIER STEFFEN (DE) | 2010-05-20 | — | — | WO | disclosed |
| EP-2186521-A1 | Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound | Steffen, Mergemeier (DE) | 2010-05-19 | — | — | EP | disclosed |
| US-7678369-B2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-7638524-B2 | For reducing serum cholesterol in a mammal | GENZYME CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | HOLMES-FARLEY STEPHEN R | 2007-08-16 | — | — | US | disclosed |
| EP-1189622-B1 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | GENZYME CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1800687-A2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1800686-A2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7125547-B2 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060134062-A1 | Polymeric boronic acid derivatives as lipase inhibitors | GENZYME CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-20060128663-A1 | Aryl boronate functionalized polymers for treating obesity | GENZYME CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
| US-7048917-B1 | Fat-binding polymers | GENZYME CORPORATION (US) | 2006-05-23 | — | — | US | disclosed |
| US-7041280-B2 | Aryl boronate functionalized polymers for treating obesity | GENZYME CORPORATION (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060029568-A1 | Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents | GENZYME CORPORATION (US) | 2006-02-09 | — | — | US | disclosed |
| EP-1043982-B1 | LIPASE INHIBITING POLYMERS | GENZYME CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6890523-B2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050085535-A1 | Lipase inhibiting polymers | GENZYME CORPORATION (US) | 2005-04-21 | — | — | US | disclosed |
| US-6875428-B2 | Lipase inhibiting polymers | GENZYME CORPORATION (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-6730295-B2 | ADMINISTERING CATIONIC POLYMERS | GENZYME CORPORATION | 2004-05-04 | — | — | US | disclosed |
| US-6726906-B1 | ORALLY ADMINISTERED POLY(N,N-DI(2,3-DIHYDROXYPROPYL) ALLYLAMINE)HYDROCHLORIDE AND TETRAHYDROLIPSTATIN LIPASE INHIBITOR; HYPERTRIGLYCERIDEMIA; SIDE EFFECT REDUCTION | GENZYME CORPORATION | 2004-04-27 | — | — | US | disclosed |
| EP-1404686-A1 | ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY | Geltex Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-6692732-B2 | Administering cationic polymers to mammals to prevent poisons or antigens from microorganisms such as bacteria, viruses, fungi or parasites; deactivation | GENZYME CORPORATION | 2004-02-17 | — | — | US | disclosed |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-20030185789-A1 | Lipase inhibiting polymers | GELTEX PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030175236-A1 | Fat-binding polymers | GELTEX PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6610283-B1 | Method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a | GENZYME CORPORATION | 2003-08-26 | — | — | US | disclosed |
| US-20030138397-A1 | Anionic polymers as toxin binders and antibacterial agents | GELTEX PHARMACEUTICALS, INC. | 2003-07-24 | — | — | US | disclosed |
| US-6572850-B1 | Treating obesity by administering a polyether substituted with a pendant B-lactone group;reduction in fat hydrolysis and absorption | GELTEX PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6558657-B1 | Synthetic polymer, carbohydrate or protein substituted with disulfide moiety that inhibits fat hydrolysis | GELTEX PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| EP-1043981-B1 | FAT-BINDING POLYMERS COMBINED WITH LIPASE INHIBITORS FOR THE TREATMENT OF OBESITY | GELTEX PHARMA INC (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030059399-A1 | Aryl boronate functionalized polymers for treating obesity | GELTEX PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | disclosed |
| EP-1028717-B1 | UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMA INC (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6517827-B1 | Polystyrene sulfonate polymer; Clostridium difficile | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6517826-B1 | Polystyrene sulfonate polymer; Clostridium difficile | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| WO-2003002571-A1 | ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY | GENZYME CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
| US-20020155091-A1 | Combination therapy for treating hypercholesterolemia | GELTEX PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | GELTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6419914-B2 | POLYMER WITH PENDANT ACID FUNCTIONAL GROUPS; WILL NOT DEGRADE IN THE GASTROINTESTINAL TRACT | GELTEX PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1196181-A1 | FAT-BINDING POLYMERS, OPTIONALLY COMBINED WITH LIPASE INHIBITORS | Geltex Pharmaceuticals, Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| US-6365186-B1 | ADMINISTERING TO PATIENT UNSUBSTITUTED POLYDIALLYLAMINE POLYMER AND CHOLESTEROL-LOWERING AGENT IN THERAPEUTICALLY EFFECTIVE AMOUNT | GELTEX PHARMACEUTICALS, INC. | 2002-04-02 | — | — | US | disclosed |
| EP-1189622-A2 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | Geltex Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-20020034491-A1 | Anionic polymers as species specific antibacterial agents | GELTEX PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| US-6352692-B1 | POLYMERS WITH PHOSPHINO-CONTAINING FUNCTIONAL GROUP SUBSTITUENTS; ORALLY ADMINISTERING TO TREAT OBESITY AND HYPERTRIGLYCERIDEMIA | GELTEX PHARMACEUTICALS, INC. | 2002-03-05 | — | — | US | disclosed |
| US-20010041171-A1 | Anionic polymers as toxin binders | GELTEX PHARMACEUTICALS, INC. (US) | 2001-11-15 | — | — | US | disclosed |
| US-6303723-B1 | POLYMERS OF ALLYLIC AMINE COMPOUNDS; AZOBIS(N-HYDROXYALKYLAMIDE) FREE RADICAL CATALYST, E.G., 2,2'-AZOBIS(2-METHYL-N-(2-HYDROXYETHYL)PROPIONAMIDE | PENN STATE RESEARCH FOUNDATION | 2001-10-16 | — | — | US | disclosed |
| US-6299868-B1 | FACILITATES THE REMOVAL OF FAT FROM THE BODY PRIOR TO DIGESTION, WITH MINIMAL SIDE EFFECTS AND LOW TOXICITY; FOR THERAPY OF OBESITY, STEATORRHEA, HYPERTRIGLYCERIDEMIA IN MAMMALS | GELTEX PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | disclosed |
| US-6294163-B1 | Polymers containing guanidinium groups as bile acid sequestrants | GELTEX PHARMACEUTICALS, INC. | 2001-09-25 | — | — | US | disclosed |
| US-6290947-B1 | IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6290946-B1 | ADMINISTERING TO THE ANIMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A POLYMER HAVING A PLURALITY OF PENDANT ACID FUNCTIONAL GROUPS WHICH ARE DIRECTLY ATTACHED TO THE POLYMER BACKBONE OR ATTACHED TO THE POLYMER BACKBONE BY A SPACER GROUP. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6271264-B1 | REMOVING BILE ACIDS FROM PATIENTS | GELTEX PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-6270755-B1 | POLYMER COMPRISING PENDANT ACID FUNCTIONAL GROUPS OR A SALT THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE CATION, SAID POLYMER COMPRISING NO ACID ANHYDRIDE GROUPS. | GELTEX PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-6267952-B1 | ORALLY ADMINISTERING TO MAMMAL A MODIFIED POLYMER WHICH FOR TREATING OBESITY | GELTEX PHARMACEUTICALS, INC. | 2001-07-31 | — | — | US | disclosed |
| US-6264937-B1 | MIXTURE WITH LIPASE INHIBITOR | GELTEX PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | disclosed |
| US-6264938-B1 | ADMINISTERING POLYDIALLYLAMINE AND HYDROXY-3-METHYLGLUTARYL/3-/, COENZYME A REDUCTASE | GELTEX PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | disclosed |
| US-6248318-B1 | ADMINISTERING DOSAGE INTO GASTROINTESTINAL TRACT | GELTEX PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6203785-B1 | ADMINISTERING CROSSLINKED CATIONIC POLYMER ANTICHOLESTEROL AGENTS | GELTEX PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| WO-2001005408-A1 | FAT-BINDING POLYMERS, OPTIONALLY COMBINED WITH LIPASE INHIBITORS | GELTEX PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000069428-A2 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069445-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069446-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-1043982-A2 | LIPASE INHIBITING POLYMERS | Geltex Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-1043981-A2 | FAT-BINDING POLYMERS COMBINED WITH LIPASE INHIBITORS | Geltex Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-1028717-A2 | UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000038664-A2 | AMINE CONDENSATION POLYMER BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| US-6083497-A | REMOVING BILE SALTS FROM A PATIENT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A NON-ABSORBABLE POLYDIALLYLAMINE POLYMER | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-2000032656-A2 | POLYMERS CONTAINING SPIROBICYCLIC AMMONIUM MOIETIES AND USE THEREOF | GELTEX PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000024791-A1 | PROCESS FOR POLYMERIZATION OF ALLYLIC COMPOUNDS | PENN STATE RESEARCH FOUNDATION (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999047587-A1 | CONTINUOUS CROSSLINKING OF POLYMER GELS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5929184-A | ANTICHOLESTEROL | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-27 | — | — | US | disclosed |
| US-5925379-A | REMOVING BILE SALTS FROM PATIENT BY ADMINISTERING INTERPENETRATING POLYMER NETWORK COMPRISING CATIONIC POLYMER | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1999034787-A2 | FAT-BINDING POLYMERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999034786-A2 | LIPASE INHIBITING POLYMERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999033452-A2 | AMINE-CONTAINING COPOLYMERS AS BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999022721-A2 | UNSUBSTITUTED POLYDIALLYLAMINE FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1999022743-A1 | POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0706535-A1 | PROCESSES FOR PREPARING AQUEOUS POLYMER EMULSIONS | UNION CARBIDE CHEM PLASTIC (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0642540-A1 | COMPLEX HYDROPHOBE COMPOUNDS, MACROMONOMERS AND MACROMONOMER-CONTAINING POLYMERS. | UNION CARBIDE CHEM PLASTIC (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1994027619-A1 | PROCESS FOR ADJUSTING ION CONCENTRATION IN A PATIENT AND COMPOSITIONS THEREFOR | GELTEX PHARMACEUTICALS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994027619-A1 | PROCESS FOR ADJUSTING ION CONCENTRATION IN A PATIENT AND COMPOSITIONS THEREFOR | GELTEX PHARMACEUTICALS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155091-A1 | Combination therapy for treating hypercholesterolemia | PCSK9, SLC10A1, NR1H4 | GABRP 3558/4885GABRD 4037/4885GABRA1 3340/4885 |
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | GABRP 2298/4885GABRD 1732/4885GABRA1 2281/4885 |
| US-20030185789-A1 | Lipase inhibiting polymers | PNLIP, LIPC, LPL | GABRP 3381/4885GABRD 3395/4885GABRA1 4065/4885 |
| US-20010041171-A1 | Anionic polymers as toxin binders | PIGS, CD47, BTD | GABRP 162/4885GABRD 401/4885GABRA1 308/4885 |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | GABRP 1785/4885GABRD 1180/4885GABRA1 1788/4885 |
| US-20100172861-A1 | Anionic Polymers as Toxin Binders and Antibacterial Agents | MSN, ANTXR2, PNKP | GABRP 254/4885GABRD 452/4885GABRA1 649/4885 |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | PIGS, ANTXR2, MSN | GABRP 53/4885GABRD 1514/4885GABRA1 440/4885 |
| US-20060134062-A1 | Polymeric boronic acid derivatives as lipase inhibitors | CEL, LIPE, LPL | GABRP 854/4885GABRD 952/4885GABRA1 987/4885 |
| US-20030059399-A1 | Aryl boronate functionalized polymers for treating obesity | CEL, AHR, LIPE | GABRP 638/4885GABRD 1673/4885GABRA1 835/4885 |
| US-20060029568-A1 | Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents | DDOST, DNPEP, IDUA | GABRP 223/4885GABRD 434/4885GABRA1 361/4885 |
| US-20050085535-A1 | Lipase inhibiting polymers | PNLIP, LIPC, LPL | GABRP 3381/4885GABRD 3395/4885GABRA1 4065/4885 |
| US-20100266526-A1 | Combination therapy for treating hypercholesterolemia | PCSK9, SLC10A1, NR1H4 | GABRP 3558/4885GABRD 4037/4885GABRA1 3340/4885 |
| US-20060128663-A1 | Aryl boronate functionalized polymers for treating obesity | CEL, AHR, LIPE | GABRP 553/4885GABRD 1285/4885GABRA1 861/4885 |
| US-20030175236-A1 | Fat-binding polymers | LIPC, LPL, PNLIP | GABRP 3855/4885GABRD 4321/4885GABRA1 4003/4885 |
| US-20030138397-A1 | Anionic polymers as toxin binders and antibacterial agents | MSN, ANTXR2, PNKP | GABRP 254/4885GABRD 452/4885GABRA1 649/4885 |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | PIGS, ANTXR2, MSN | GABRP 53/4885GABRD 1514/4885GABRA1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.